Remdesivir does not cause clinically relevant QT interval prolongation, according to a Phase 1 clinical trial evaluating supratherapeutic intravenous doses of the antiviral medication. The findings offer new clinical safety data for treating COVID-19 patients, who already face elevated risks of cardiac complications and mortality linked to delayed heart repolarization.
Trial Clears Remdesivir of Cardiac Risks
Testing Triple the Standard Loading Dose
Researchers examined the safety, tolerability, pharmacokinetics, and cardiac repolarization effects of a single 600-mg intravenous dose of remdesivir—three times the standard 200-mg loading dose approved for COVID-19 treatment. The study also assessed the safety of the drug’s solubilizing excipient, sulfobutylether-beta-cyclodextrin (SBECD).
Sixty healthy participants completed the trial across two cohorts: an initial dose-selection sentinel cohort followed by a partially blinded, randomized, placebo- and positive-controlled crossover cohort. Clinical endpoints monitored adverse events, laboratory abnormalities, plasma pharmacokinetic parameters, and baseline-adjusted, placebo-corrected QTc intervals calculated using the Fridericia formula ($DeltaDelta$QTcF).
Rapid Excipient Clearance and Clean Safety Data
The trial recorded no significant differences in plasma pharmacokinetics for remdesivir and its metabolites between the study cohorts. The solubilizing excipient SBECD cleared within 24 hours of administration, displaying no pharmacokinetic non-linearities.
Investigators observed no clinically relevant QTc prolongation compared to placebo following the supratherapeutic 600-mg dose. Most reported adverse events were mild to moderate in severity, with no serious adverse events or deaths recorded during the study.
Bolstering Antiviral Protocols for Hospitalized Patients
Patients hospitalized with COVID-19 frequently face an increased risk of cardiac complications, and baseline QT prolongation correlates with higher mortality and disease severity. While other oral antiviral treatments used for COVID-19 carry potential cardiovascular adverse effects, clinical data regarding remdesivir’s cardiac safety profile at elevated doses were previously limited.
This Phase 1 evaluation demonstrates that high-dose remdesivir does not pose a significant risk of clinically relevant QT interval prolongation. The results support the drug’s established safety profile and provide clinicians with additional cardiac safety data when administering the antiviral therapy.
Worth a look